Urgent Action Required: Viatris Investors Have Until June 3 to Protect Profits in Ongoing Securities Fraud Lawsuit

Investors who purchased shares of Viatris Inc. (NASDAQ: VTRS) between August 8, 2024, and February 26, 2025, now face a critical deadline to safeguard their interests. A recently filed securities fraud class action alleges that Viatris and its executives misled investors about the operational status of its Indore, India facility, artificially inflating stock prices before a devastating FDA warning triggered a 15% plunge in its share value. With only 11 days remaining to seek lead plaintiff status, investors must act swiftly to preserve their rights.

The Allegations: A Pattern of Deception

The lawsuit, Quinn v. Viatris Inc. (No. 25-cv-466), accuses the company of systematically downplaying critical risks tied to its Indore facility. Key claims include:
- False Assurances on Quality: Viatris repeatedly stated the facility was in “good operating condition” and met “highest quality standards,” despite internal knowledge of severe compliance issues.
- Downplaying the FDA Warning: When the U.S. Food and Drug Administration (FDA) issued a December 2024 warning letter citing “systemic deficiencies,” Viatris dismissed it as a “little bit of headwind” and claimed ongoing discussions to secure exemptions. In reality, these issues led to a $500 million revenue shortfall and a $385 million drop in operational earnings for 2025.
- The Fallout: On February 27, 2025, Viatris admitted it could not secure FDA exemptions for its Lenalidomide drug, a blockbuster treatment for multiple myeloma. The revelation caused VTRS shares to collapse from $11.24 to $9.53 in a single day.

Why This Matters for Investors

The lawsuit argues that Viatris's misstatements created a “pump and dump” scenario, where inflated stock prices were unsustainable once the truth emerged. Investors who bought during the Class Period may be entitled to compensation for losses caused by this alleged fraud. However, the clock is ticking:

• Lead Plaintiff Deadline: June 3, 2025. Investors seeking to represent the class must file motions by this date. While not required to participate in recovery, failing to act could limit future claims.
• Recovery Potential: The case is being handled by top-tier plaintiff firms, including Bleichmar Fonti & Auld LLP (ranked #5 by ISS SCAS in 2023) and Robbins Geller Rudman & Dowd LLP (ranked #1 for recoveries, including the historic $7.2B Enron settlement). Their track records suggest a strong likelihood of pursuing maximum accountability.

What to Do Next

1. Act by June 3: Contact a qualified securities attorney to submit a lead plaintiff motion. Even if you don't seek lead status, register for case updates to stay informed.
2. Choose a Reputable Firm: Prioritize firms with contingency fee structures (no upfront costs) and proven recoveries. Examples include:
3. Bleichmar Fonti & Auld LLP: +1-212-789-3619 or ross@bfalaw.com.
4. The Gross Law Firm: +1-646-453-8903 or dg@securitiesclasslaw.com.
5. Stay Informed: Monitor VTRS's regulatory filings and FDA updates for further developments.

The Bottom Line: Time is Running Out

Investors holding VTRS shares during the Class Period are sitting on a ticking clock. With millions in potential losses at stake and seasoned legal teams ready to act, the path forward is clear: Act before June 3 to protect your rights.

The stakes could not be higher. This is not merely a legal technicality—it's a chance to hold corporate wrongdoers accountable and reclaim value lost to deception. Don't let this opportunity slip away.

This article is for informational purposes only. Investors are urged to consult with legal counsel to discuss their specific circumstances.